Identification of specific biomarkers for breast cancer cells
First Claim
Patent Images
1. A composition comprising at least one expression vector, wherein the at least one expression vector comprises a nucleic acid comprising:
- (a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a polynucleotide sequence complementary thereto;
(b) at least one polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
or, (f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto.
1 Assignment
0 Petitions
Accused Products
Abstract
Nucleic acids, proteins, antibodies, marker sets and arrays are provided for biomarkers for breast cancer. Methods for detecting breast cancer, modulating breast cancer phenotypes in cells, and for treating a subject with breast cancer are also provided.
-
Citations
92 Claims
-
1. A composition comprising at least one expression vector, wherein the at least one expression vector comprises a nucleic acid comprising:
-
(a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a polynucleotide sequence complementary thereto;
(b) at least one polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
or,(f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. An isolated or recombinant polypeptide comprising:
one or more amino acid sequences or subsequences encoded by a nucleic acid comprising;
(a) an amino acid sequence of SEQ ID NO;
492, and conservative variants thereof;
(b) an amino acid sequence encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO;
1 to SEQ ID NO;
491, and conservative variations thereof;
(c) an amino acid sequence encoded by a polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence selected from the group consisting of SEQ ID NO;
1 to SEQ ID NO;
491(d) an amino acid sequence encoded by a polynucleotide sequence that is at least about 70% identical to a polynucleotide selected from the group consisting of SEQ ID NO;
1 to SEQ ID NO;
491;
or(e) a polypeptide comprising an amino acid subsequence of (a), (b), (c) or (d). - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
25. A labeled probe comprising a nucleic acid or polypeptide comprising:
-
(a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a polynucleotide sequence complementary thereto;
(b) at least one polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
(f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto;
(g) at least one polypeptide or peptide comprising an amino acid sequence of SEQ ID NO;
492 or conservative variations thereof;
(h) at least one polypeptide or peptide comprising an amino acid subsequence of SEQ ID NO;
492, or conservative variants thereof comprising at least six amino acids;
or,(i) at least one antibody specific for a polypeptide or peptide sequence of (g) or (h). - View Dependent Claims (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A marker set for predicting at least one characteristic of a breast cancer cell, comprising a plurality of members, which members comprise:
-
(a) one or more polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a polynucleotide sequence complementary thereto;
(b) one or more polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) one or more polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) one or more polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) one or more polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a) or (b);
(f) one or more polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto;
(g) one or more polypeptide comprising an amino acid sequence or subsequence of SEQ ID NO;
492 or conservative variants thereof comprising at least six amino acids; and
/or,(h) one or more antibodies specific for a polypeptide or peptide sequence of (g) or encoded by (c). - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
-
-
56. A method for modulating at least one characteristic of a breast cell, the method comprising:
modulating expression or activity of at least one polypeptide encoded by a nucleic acid, the nucleic acid comprising;
(a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a sequence complementary thereto;
(b) at least one polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
or,(f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto.- View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)
-
71. A method for identifying a breast cancer gene, the method comprising:
-
(i) providing at least one nucleic acid comprising;
(a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a polynucleotide sequence complementary thereto;
(b) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(c) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(d) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
(e) at least one polynucleotide sequence that hybridizes to a nucleic acid that is physically linked in the human genome to a nucleic acid comprising a polynucleotide sequence of (a), (b), (c) or (d);
or,(f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto; and
,(ii) identifying at least one nucleic acid corresponding to a breast cancer gene. - View Dependent Claims (72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 91)
-
-
88. A method of detecting breast cancer in a subject, the method comprising:
-
(i) providing a subject cell or tissue sample of nucleic acids; and
,(ii) detecting at least one polymorphic nucleic acid or at least one expression product corresponding to a polynucleotide sequence comprising;
(a) at least one polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491 or a polynucleotide sequence complementary thereto;
(b) at least one polynucleotide sequence comprising a conservative variation of a polynucleotide sequence of (a);
(c) at least one polynucleotide encoding a polypeptide sequence of SEQ ID NO;
492, or conservative variations thereof;
(d) at least one polynucleotide sequence that hybridizes under stringent conditions to a polynucleotide sequence of (a) or (b);
(e) at least one polynucleotide that is at least about 70% identical to a polynucleotide sequence of (a), or (b);
or,(f) at least one polynucleotide sequence comprising at least about 10 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of;
SEQ ID NO;
1-SEQ ID NO;
491, or a sequence complementary thereto,wherein the polymorphic nucleic acid or expression or activity of the expression product is correlatable to breast cancer. - View Dependent Claims (89, 90, 92)
-
Specification